Johnson Tali M
Pharmaceutical Management Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, 6130 Executive Blvd Room 7149, MSC 7422, Rockville, MD 20852.
Consult Pharm. 2011 Jun;26(6):390-9. doi: 10.4140/TCP.n.2011.390.
As the number of men in the United States 65 years of age or older increases--from 12% in 2000 to 20% in 2030--the burden of prostate cancer also is increasing. Standard therapy is appropriate for healthy men with a life expectancy of more than 10 years; however, clinicians may fear either overtreating frail patients or undertreating patients who are physically fit. Evidence suggests the best approach is to conduct a comprehensive geriatric assessment using available measures and published guidelines to individualize treatment plans. Recent Food and Drug Administration approval of cabazitaxel, sipuleucel-T, and denosumab has expanded available treatment options. Managing symptoms related to disease complications and side effects of treatment is increasingly more complicated with the addition of these new regimens and extended life expectancy. Pharmacists' participation in patient assessment and supportive care are necessary components of comprehensive care for cancer patients.
在美国，65岁及以上男性的数量不断增加，从2000年的12%增至2030年的20%，前列腺癌的负担也在加重。标准疗法适用于预期寿命超过10年的健康男性；然而，临床医生可能担心对体弱患者过度治疗或对身体状况良好的患者治疗不足。有证据表明，最佳方法是采用现有措施并依据已发布的指南进行全面的老年综合评估，以制定个性化的治疗方案。美国食品药品监督管理局最近批准了卡巴他赛、 sipuleucel-T和地诺单抗，从而扩大了可用的治疗选择。随着这些新疗法的增加以及预期寿命的延长，处理与疾病并发症和治疗副作用相关的症状变得越来越复杂。药剂师参与患者评估和支持性护理是癌症患者综合护理的必要组成部分。
